Intra-tumor heterogeneity can be estimated by diversity-based summary statistics that can be leveraged to predict clinical outcomes.
Investigating the underlying evolutionary dynamics of clonal hematopoietic diseases such as myelodysplastic syndromes and chronic myelomonocytic leukemia is important to understand where the heterogeneous clinical presentation of these malignancies with a limited amount of genomic heterogenetic. To this end, my efforts have focused on quantifying heterogeneity in tumor samples, compared to healthy cases, in attempts to identify key phenotypic signatures that can ultimately be used prognostically in the clinical setting.